Published : 25.08.2020
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward building the company’s international scientific cooperation platform.
Published : 24.07.2020
Jerzy Starak’s billions invested in Polpharma Biologics are going to soon bear fruit in the form of new biosimilar drugs
Published : 13.07.2020
Bioceros is now Polpharma Biologics.
Published : 10.02.2020
Polpharma Biologics is a fast-growing business that develops and manufactures biopharmaceuticals as new molecular entities (NMEs) or biosimilars, and also delivers biopharmaceutical CDMO services.
Published : 03.09.2019
Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine.
Published : 22.12.2018
Process optimisation for biologics is obligatory for efficient processing and reduction of Cost of Goods (COGs). Especially in the development of biosimilar antibodies, low COGs to manufacture the antibody provides a competitive advantage compared to competing biosimilar developers.
Published : 28.09.2018
Polpharmа Biologics Group conducts business in compliance with the highest ethical standards, adhering to its established system of values which is based on compliance, honesty, responsibility and cooperation.
Published : 07.05.2018
Building a biologics business from the ground up provides tremendous flexibility but requires the right business strategy. Polpharma has attracted worldrecognized leaders to build and manage all key biologics funcions at its new, state-of-the-art facilities, which are located in Poland and in the Netherlands, ideally situated to serve the global markets.
Find out about all the latest developments of our portfolio and our partners products and other news from Polpharma Biologics.See all
We have an extensive catalogue of videos introducing our sites, solutions, portfolio and employment opportunities.See all
We attend all the major biologics conferences globally as invited speakers, exhibitors and sponsors, find out where we will be below.See all